| 臺大學術典藏 |
2020-06-30T08:10:05Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.;Ho C.-C.;Hsia T.-C.;Tseng J.-S.;Kang-Yi Su;Wu M.-F.;Chiu K.-L.;Yang T.-Y.;Chen K.-C.;Ooi H.;Wu T.-C.;Chen H.-J.;Chen H.-Y.;Chang C.-S.;Hsu C.-P.;Hsia J.-Y.;Chuang C.-Y.;Lin C.-H.;Chen J.J.W.;Chen K.-Y.;Liao W.-Y.;Shih J.-Y.;Yu S.-L.;Yu C.-J.;Yang P.-C.;Chang G.-C.; Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; KANG-YI SU; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2020-06-30T08:10:03Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.;Chen K.-C.;Hsu K.-H.;Tseng J.-S.;Ho C.-C.;Hsia T.-C.;Kang-Yi Su;Wu M.-F.;Chiu K.-L.;Liu C.-M.;Wu T.-C.;Chen H.-J.;Chen H.-Y.;Chang C.-S.;Hsu C.-P.;Hsia J.-Y.;Chuang C.-Y.;Lin C.-H.;Chen J.J.W.;Chen K.-Y.;Liao W.-Y.;Shih J.-Y.;Yu S.-L.;Yu C.-J.;Yang P.-C.;Yang T.-Y.;Chang G.-C.; Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; KANG-YI SU; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2020-06-30T08:09:57Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:56Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Kang-Yi Su;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; KANG-YI SU; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-06-30T08:09:52Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:51Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-16T06:32:18Z |
Rapid atmospheric-pressure-plasma-jet processed porous materials for energy harvesting and storage devices
|
Chen, J.-Z.;Hsu, C.-C.;Wang, C.;Liao, W.-Y.;Wu, C.-H.;Wu, T.-J.;Liu, H.-W.;Chang, H.;Lien, S.-T.;Li, H.-C.;Hsu, C.-M.;Kao, P.-K.;Yang, Y.-J.;Cheng, I.-C.; Chen, J.-Z.; Hsu, C.-C.; Wang, C.; Liao, W.-Y.; Wu, C.-H.; Wu, T.-J.; Liu, H.-W.; Chang, H.; Lien, S.-T.; Li, H.-C.; Hsu, C.-M.; Kao, P.-K.; Yang, Y.-J.; Cheng, I.-C.; I-CHUN CHENG |
| 臺大學術典藏 |
2020-06-16T06:32:11Z |
Atmospheric-pressure-plasma-jet sintered dual-scale porous TiO2 using an economically favorable NaCl solution
|
Liao, W.-Y.;Yang, Y.-J.;Hsu, C.-M.;Hsu, C.-C.;Cheng, I.-C.;Chen, J.-Z.; Liao, W.-Y.; Yang, Y.-J.; Hsu, C.-M.; Hsu, C.-C.; Cheng, I.-C.; Chen, J.-Z.; I-CHUN CHENG |
| 臺大學術典藏 |
2020-06-16T06:32:08Z |
Oxygen-deficient indium tin oxide thin films annealed by atmospheric pressure plasma jets with/without air-quenching
|
Liao, W.-Y.;Chang, H.;Yang, Y.-J.;Hsu, C.-C.;Cheng, I.-C.;Chen, J.-Z.; Liao, W.-Y.; Chang, H.; Yang, Y.-J.; Hsu, C.-C.; Cheng, I.-C.; Chen, J.-Z.; I-CHUN CHENG |
| 臺大學術典藏 |
2020-05-26T09:27:09Z |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
|
Yu C.-J.;Chen Y.-M;Chih-Hsin Yang;Cheng Y.-K;Chang G.-C;Shih J.-Y;Liao W.-Y; Liao W.-Y; Shih J.-Y; Chang G.-C; Cheng Y.-K; CHIH-HSIN YANG; Chen Y.-M; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Survival of lung adenocarcinoma patients with malignant pleural effusion
|
Wu S.-G;Yu C.-J;Tsai M.-F;Liao W.-Y;Chih-Hsin Yang;Jan I.-S;Yang P.-C;Shih J.-Y.; Wu S.-G; Yu C.-J; Tsai M.-F; Liao W.-Y; CHIH-HSIN YANG; Jan I.-S; Yang P.-C; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-26T09:27:02Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Liao W.-Y;Chen J.-H;Wu M;Shih J.-Y;Chen K.-Y;Ho C.-C;Chih-Hsin Yang;Yu C.-J.; Liao W.-Y; Chen J.-H; Wu M; Shih J.-Y; Chen K.-Y; Ho C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H;Yang C.-Y;Ho C.-C;Liao W.-Y;Jan I.-S;Chen K.-Y;Wang J.-Y;Ruan S.-Y;Yu C.-J;Chih-Hsin Yang;Yang P.-C;Shih J.-Y.; Tsai T.-H; Yang C.-Y; Ho C.-C; Liao W.-Y; Jan I.-S; Chen K.-Y; Wang J.-Y; Ruan S.-Y; Yu C.-J; CHIH-HSIN YANG; Yang P.-C; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Yang P.-C.;Rosell R;Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Yu K.-L;Liao W.-Y;Su K.-Y;Ruan S.-Y;Molina-Vila M.A;Chen L.-Y; Chen L.-Y; Molina-Vila M.A; Ruan S.-Y; Su K.-Y; Liao W.-Y; Yu K.-L; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG; Rosell R; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
|
Shih J.-Y; Yu C.-J; Chih-Hsin CHIH-HSIN YANG; Lin C.-A; Liao W.-Y; Ho C.-C; Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Lin C.-A;Liao W.-Y;Ho C.-C |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.;Chih-Hsin Yang;Lin C.-C;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:28Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non?�Small-cell Lung Cancer Patients
|
Wu T.-H; Hsiue E.H.-C; Lee J.-H; Lin C.-C; Liao W.-Y; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG; Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Liao W.-Y;Lin C.-C;Lee J.-H;Hsiue E.H.-C;Wu T.-H |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T;Chen J.-S;Liao W.-Y;Ho C.-C;Hsu C.-L;Yang C.-Y;Chen K.-Y;Lee J.-H;Lin Z.-Z;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Lin Y.-T; Chen J.-S; Liao W.-Y; Ho C.-C; Hsu C.-L; Yang C.-Y; Chen K.-Y; Lee J.-H; Lin Z.-Z; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non?�small-cell lung cancer patients
|
Yao Z.-H;Liao W.-Y;Ho C.-C;Chen K.-Y;Shih J.-Y;Chen J.-S;Lin Z.-Z;Lin C.-C;Chih-Hsin Yang;Yu C.-J.; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Hsu F.-M;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Chih-Hsin Yang; Lee J.-H; Chen H.-Y; Hsu F.-M; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Exon 16?�Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M?�Positive Non?�Small Cell Lung Cancer
|
Hsu C.-C;Liao B.-C;Liao W.-Y;Markovets A;Stetson D;Thress K;Chih-Hsin Yang; Hsu C.-C; Liao B.-C; Liao W.-Y; Markovets A; Stetson D; Thress K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y;Liao W.-Y;Ho C.-C;Chen K.-Y;Tsai T.-H;Hsu C.-L;Su K.-Y;Chang Y.-L;Wu C.-T;Hsu C.-C;Liao B.-C;Hsu W.-H;Lee J.-H;Lin C.-C;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
